Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination.

Raeven RHM, Brummelman J, Pennings JLA, van der Maas L, Helm K, Tilstra W, van der Ark A, Sloots A, van der Ley P, van Eden W, Jiskoot W, van Riet E, van Els CACM, Kersten GFA, Han WGH, Metz B.

Mucosal Immunol. 2018 May;11(3):1009. doi: 10.1038/mi.2017.110. Epub 2018 Feb 7.

PMID:
29411776
2.

Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination.

Raeven RH, Brummelman J, Pennings JLA, van der Maas L, Helm K, Tilstra W, van der Ark A, Sloots A, van der Ley P, van Eden W, Jiskoot W, van Riet E, van Els CA, Kersten GF, Han WG, Metz B.

Mucosal Immunol. 2018 May;11(3):979-993. doi: 10.1038/mi.2017.81. Epub 2017 Sep 20. Erratum in: Mucosal Immunol. 2018 Feb 07;:.

PMID:
28930286
3.

Reporter cell lines for detection of pertussis toxin in acellular pertussis vaccines as a functional animal-free alternative to the in vivo histamine sensitization test.

Hoonakker ME, Verhagen LM, van der Maas L, Sloots A, Hendriksen CFM.

Vaccine. 2017 Feb 22;35(8):1152-1160. doi: 10.1016/j.vaccine.2017.01.011. Epub 2017 Jan 24.

4.

Proteome Analysis Is a Valuable Tool to Monitor Antigen Expression during Upstream Processing of Whole-Cell Pertussis Vaccines.

Metz B, Hoonakker M, Uittenbogaard JP, Weyts M, Mommen GP, Meiring HD, Tilstra W, Pennings JL, van der Pol LA, Kuipers B, Sloots A, van den IJssel J, van de Waterbeemd B, van der Ark A.

J Proteome Res. 2017 Feb 3;16(2):528-537. doi: 10.1021/acs.jproteome.6b00668. Epub 2016 Dec 23.

PMID:
27977922
5.

Vaccine-Mediated Activation of Human TLR4 Is Affected by Modulation of Culture Conditions during Whole-Cell Pertussis Vaccine Preparation.

Hoonakker ME, Verhagen LM, Pupo E, de Haan A, Metz B, Hendriksen CF, Han WG, Sloots A.

PLoS One. 2016 Aug 22;11(8):e0161428. doi: 10.1371/journal.pone.0161428. eCollection 2016.

6.

Adaptive immune response to whole cell pertussis vaccine reflects vaccine quality: A possible complementation to the Pertussis Serological Potency test.

Hoonakker ME, Verhagen LM, van der Maas L, Metz B, Uittenbogaard JP, van de Waterbeemd B, van Els CA, van Eden W, Hendriksen CF, Sloots A, Han WG.

Vaccine. 2016 Aug 17;34(37):4429-36. doi: 10.1016/j.vaccine.2016.07.011. Epub 2016 Jul 21.

PMID:
27452867
7.

In vitro innate immune cell based models to assess whole cell Bordetella pertussis vaccine quality: a proof of principle.

Hoonakker ME, Verhagen LM, Hendriksen CF, van Els CA, Vandebriel RJ, Sloots A, Han WG.

Biologicals. 2015 Mar;43(2):100-9. doi: 10.1016/j.biologicals.2014.12.002. Epub 2015 Jan 26.

PMID:
25633359
8.

Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.

van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, Boon L, Smit VT, Welters MJ, Ossendorp F, van de Water B, Arens R, van der Burg SH, Melief CJ.

Clin Cancer Res. 2015 Feb 15;21(4):781-94. doi: 10.1158/1078-0432.CCR-14-2142. Epub 2014 Dec 12.

9.

Bordetella pertussis naturally occurring isolates with altered lipooligosaccharide structure fail to fully mature human dendritic cells.

Brummelman J, Veerman RE, Hamstra HJ, Deuss AJ, Schuijt TJ, Sloots A, Kuipers B, van Els CA, van der Ley P, Mooi FR, Han WG, Pinelli E.

Infect Immun. 2015 Jan;83(1):227-38. doi: 10.1128/IAI.02197-14. Epub 2014 Oct 27.

10.

Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses.

Afonso-Barroso A, Clark SO, Williams A, Rosa GT, Nóbrega C, Silva-Gomes S, Vale-Costa S, Ummels R, Stoker N, Movahedzadeh F, van der Ley P, Sloots A, Cot M, Appelmelk BJ, Puzo G, Nigou J, Geurtsen J, Appelberg R.

Cell Microbiol. 2013 Apr;15(4):660-74. doi: 10.1111/cmi.12065. Epub 2012 Nov 21.

PMID:
23121245
11.

IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.

Burkhardt UE, Sloots A, Jakobi V, Wei WZ, Cavallo F, Kloke BP, Wels WS.

Cancer Immunol Immunother. 2012 Sep;61(9):1473-84. doi: 10.1007/s00262-012-1215-7. Epub 2012 Feb 14.

PMID:
22331080
12.

DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.

Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jäger E, Forni G, Cavallo F, Wels WS.

Clin Cancer Res. 2008 Nov 1;14(21):6933-43. doi: 10.1158/1078-0432.CCR-08-1257.

14.

Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.

Rohrbach F, Weth R, Kursar M, Sloots A, Mittrücker HW, Wels WS.

J Immunol. 2005 May 1;174(9):5481-9.

Supplemental Content

Loading ...
Support Center